Tarek Elbeik

3.2k total citations
43 papers, 2.5k citations indexed

About

Tarek Elbeik is a scholar working on Virology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Tarek Elbeik has authored 43 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Virology, 28 papers in Infectious Diseases and 17 papers in Epidemiology. Recurrent topics in Tarek Elbeik's work include HIV Research and Treatment (33 papers), HIV/AIDS drug development and treatment (22 papers) and HIV/AIDS Research and Interventions (18 papers). Tarek Elbeik is often cited by papers focused on HIV Research and Treatment (33 papers), HIV/AIDS drug development and treatment (22 papers) and HIV/AIDS Research and Interventions (18 papers). Tarek Elbeik collaborates with scholars based in United States, Australia and United Kingdom. Tarek Elbeik's co-authors include Robert M. Grant, Mark B. Feinberg, Pedro Barbosa, Steven G. Deeks, Richard Loftus, Frederick Hecht, Silvija I. Staprans, Susan Buchbinder, Melinda Swanson and Spyros A. Kalams and has published in prestigious journals such as New England Journal of Medicine, The Journal of Experimental Medicine and Annals of Internal Medicine.

In The Last Decade

Tarek Elbeik

42 papers receiving 2.4k citations

Peers

Tarek Elbeik
S. A. Danner Netherlands
Barry M. Bredt United States
Huyen Cao United States
Rika Draenert Germany
Ven Natarajan United States
Oren J. Cohen United States
Mary Warrell United Kingdom
Bárbara Schmidt Germany
Benoît Trottier Canada
C. McLaren United States
S. A. Danner Netherlands
Tarek Elbeik
Citations per year, relative to Tarek Elbeik Tarek Elbeik (= 1×) peers S. A. Danner

Countries citing papers authored by Tarek Elbeik

Since Specialization
Citations

This map shows the geographic impact of Tarek Elbeik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tarek Elbeik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tarek Elbeik more than expected).

Fields of papers citing papers by Tarek Elbeik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tarek Elbeik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tarek Elbeik. The network helps show where Tarek Elbeik may publish in the future.

Co-authorship network of co-authors of Tarek Elbeik

This figure shows the co-authorship network connecting the top 25 collaborators of Tarek Elbeik. A scholar is included among the top collaborators of Tarek Elbeik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tarek Elbeik. Tarek Elbeik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Elbeik, Tarek, et al.. (2007). HIV-1 and HCV viral load cost models for bDNA: 440 Molecular System versus real-time PCR AmpliPrep®/TaqMan®test. Expert Review of Molecular Diagnostics. 7(6). 723–753. 6 indexed citations
2.
Elbeik, Tarek, et al.. (2007). Cost assessment of the automated VERSANT™ 440 Molecular System versus the semi-automated System 340 bDNA Analyzer platforms. Expert Review of Molecular Diagnostics. 7(6). 713–722. 1 indexed citations
3.
Roland, Michelle E., Tarek Elbeik, James O. Kahn, et al.. (2004). HIV RNA Testing in the Context of Nonoccupational Postexposure Prophylaxis. The Journal of Infectious Diseases. 190(3). 598–604. 11 indexed citations
4.
Elbeik, Tarek, et al.. (2003). Global cost modeling analysis of HIV-1 and HCV viral load assays. Expert Review of Pharmacoeconomics & Outcomes Research. 3(4). 383–407. 11 indexed citations
5.
Gleaves, Curt A., Tarek Elbeik, Valerie L. Ng, et al.. (2002). Multicenter evaluation of the Bayer VERSANT™ HIV-1 RNA 3.0 assay: analytical and clinical performance. Journal of Clinical Virology. 25(2). 205–216. 44 indexed citations
6.
Elbeik, Tarek, W. Gregory Alvord, Rapee Trichavaroj, et al.. (2002). Comparative Analysis of HIV-1 Viral Load Assays on Subtype Quantification: Bayer Versant HIV-1 RNA 3.0 Versus Roche Amplicor HIV-1 Monitor Version 1.5. JAIDS Journal of Acquired Immune Deficiency Syndromes. 29(4). 330–339. 52 indexed citations
7.
Marlowe, Natalia, B Hoo, M. Buimer, et al.. (2000). PERFORMANCE OF THE NEW VIROSEQ ™ HIV-1 GENOTYPING SYSTEM (VERSION 2) WITH GROUP M SUBTYPE PANEL AND WITH SUBTYPE B CLINICAL RESEARCH SAMPLES AT TEST SITES. AIDS. 14. 3 indexed citations
8.
Grant, Robert M., Eric A. Collisson, Gustavo Reyes‐Terán, et al.. (1999). Short Communication Antibody and Cellular Immune Responses in Breakthrough Infection Subjects after HIV Type 1 Glycoprotein 120 Vaccination. AIDS Research and Human Retroviruses. 15(18). 1685–1689. 23 indexed citations
9.
Deeks, Steven G., Frederick Hecht, Melinda Swanson, et al.. (1999). HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 13(6). F35–F43. 354 indexed citations
10.
Haslett, Patrick, Jeffrey D. Klausner, Sanit Makonkawkeyoon, et al.. (1999). Thalidomide Stimulates T Cell Responses and Interleukin 12 Production in HIV-Infected Patients. AIDS Research and Human Retroviruses. 15(13). 1169–1179. 76 indexed citations
11.
Fiscus, Susan A., Michael D. Hughes, Janet L. Lathey, et al.. (1998). Changes in Virologic Markers as Predictors of CD4 Cell Decline and Progression of Disease in Human Immunodeficiency Virus Type 1‐Infected Adults Treated with Nucleosides. The Journal of Infectious Diseases. 177(3). 625–633. 22 indexed citations
12.
Lathey, Janet L., Michael D. Hughes, Susan A. Fiscus, et al.. (1998). Variability and Prognostic Values of Virologic and CD4 Cell Measures in Human Immunodeficiency Virus Type 1‐Infected Patients with 200–500 CD4 Cells/mm3(ACTG 175). The Journal of Infectious Diseases. 177(3). 617–624. 38 indexed citations
13.
14.
Katzenstein, David, Scott M. Hammer, Michael D. Hughes, et al.. (1996). The Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in HIV-Infected Adults with 200 to 500 CD4 Cells per Cubic Millimeter. New England Journal of Medicine. 335(15). 1091–1098. 393 indexed citations
15.
Hartley, Carol A., et al.. (1996). Human Immunodeficiency Virus Grown in CD4-Expressing Cells is Associated with CD4. Journal of General Virology. 77(9). 2015–2023. 1 indexed citations
16.
Staprans, Silvija I., Betty L. Hamilton, Stephen Follansbee, et al.. (1995). Activation of virus replication after vaccination of HIV-1-infected individuals.. The Journal of Experimental Medicine. 182(6). 1727–1737. 249 indexed citations
17.
Safrin, Sharon, Tarek Elbeik, & John Mills. (1994). A Rapid Screen Test for In Vitro Susceptibility of Clinical Herpes Simplex Virus Isolates. The Journal of Infectious Diseases. 169(4). 879–882. 20 indexed citations
18.
19.
Crowe, Suzanne M., John Mills, Tarek Elbeik, et al.. (1992). Human immunodeficiency virus-infected monocyte-derived macrophages express surface GP120 and fuse with CD4 lymphoid cells in vitro: A possible mechanism of T lymphocyte depletion in vivo. Clinical Immunology and Immunopathology. 65(2). 143–151. 23 indexed citations
20.
Crowe, Suzanne M., Tarek Elbeik, Paul P. Ulrich, John Mills, & Andrew R. Moss. (1991). Lack of evidence of occult human immunodeficiency virus in seronegative individuals at very high risk of infection. Journal of Medical Virology. 35(3). 160–164. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. A. Danner Breakdown of academic impact, for papers by Barry M. Bredt Breakdown of academic impact, for papers by Huyen Cao Breakdown of academic impact, for papers by Rika Draenert Breakdown of academic impact, for papers by Ven Natarajan Breakdown of academic impact, for papers by Oren J. Cohen Breakdown of academic impact, for papers by Mary Warrell Breakdown of academic impact, for papers by Bárbara Schmidt Breakdown of academic impact, for papers by Benoît Trottier Breakdown of academic impact, for papers by C. McLaren
Rankless by CCL
2026